The Evolving Door? What Having A ‘Big Data’ Commissioner Might Mean For US FDA
Executive Summary
Robert Califf’s nomination to return as FDA commissioner will raise protests about a ‘revolving door’ pathway between industry and agency. But, in this case, it may be more apt to talk about how Califf’s time outside FDA led to evolving views on the role of big data in drug regulation.
You may also be interested in...
Pregnancy Safety Could Transform US FDA Sentinel Role In Post-Marketing Studies
As part of the new user fee agreement, FDA will develop its active surveillance safety network into a reliable tool for post-marketing pregnancy safety studies. A review of the opportunities to use the Sentinel system more broadly shows that could be an important enhancement for industry.
Real-Word Evidence Generation System Will Be A Priority For Califf As FDA Commissioner
At his Senate confirmation hearing, Robert Califf said he wants to establish a system, built on electronic medical records, that can be used to more quickly confirm the benefits and risks of accelerated approval drugs.
Califf Outlines Clinical Trial Reform Message, Which Could Travel With Him To Commissioner’s Office
US FDA commissioner-nominee Califf calls for streamlining clinical trial bureaucracy, as well as open access to clinical data.